Sunday 18 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (96.10%) | (46.09%) | 0.00% | (44.72%) |
+8 more TTM periods Free account |
|
| (36.20%) | (30.02%) | 0.00% | (17.49%) | ||
ROIC |
(245.79%) | 0.00% | 0.00% | (71.72%) | |
Return on Tangible Assets |
(48.39%) | (29.40%) | 0.00% | (35.26%) | |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.04) | 0.00 | — | 0.00 | |
Free Cash Flow |
(30.16) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(99.60%) | 0.00% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | — | 0.00 | — | |
Average Days of Payables |
0.00 | — | 0.00 | — | |
Tax Rate |
(0.10) | (0.14) | — | (0.17) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 93.71% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 69.49% | |
Share Based Compensation of Revenue |
0.00% | — | — | 0.00% | |
Interest Coverage |
(2.84) | (2.71) | — | (2.05) | |
Operating CF/Net income |
3.98 | 0.00 | — | 0.00 | |
Depreciation/Fixed assets |
0.36 | — | 0.00 | — | |
Capex/Depreciation |
0.00 | — | — | — | |
Revenue per Share |
0.00 | 0.00 | — | 1.68 | |
Operating CF per Share |
(4.04) | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates